Clinical Trials
Tavapadon helps early Parkinson's motor symptoms
In the phase 3 TEMPO-1 trial, adults with early Parkinson's disease who took tavapadon, an oral once-daily D1/D5 agonist, had significantly better motor scores than those on placebo over 26 weeks at both 5 mg and 15 mg doses. The treatment was generally well tolerated, offering patients a potential new non-levodopa option in early disease. Results were published in JAMA Neurology. *
pubmed.ncbi.nlm.nih.govAdaptive deep brain stimulation reduces falls
A randomized crossover study in Nature Medicine showed that gait-phase-synchronized adaptive deep brain stimulation was feasible, safe, and reduced falls compared with continuous stimulation in Parkinson's patients. The system adjusts stimulation in real time during walking, addressing a leading cause of injury in this population. Findings were reported online on June 15, 2026. *
pubmed.ncbi.nlm.nih.govStem cell transplant trial opens for Parkinson's
A new phase 1 trial listed on ClinicalTrials.gov will transplant midbrain dopaminergic progenitor cells made from each participant's own skin cells into the putamen of people with Parkinson's disease. The open-label study will assess safety and tolerability of this personalized cell-replacement approach, which could eventually restore dopamine production. The record was first posted on March 25, 2026. *
clinicaltrials.gov
Breakthrough Treatments
Adaptive deep brain stimulation reviewed for advanced Parkinson's
A Lancet therapeutics paper synthesizes the clinical evidence for adaptive deep brain stimulation, which adjusts stimulation in real time using subthalamic beta-band neural signals rather than delivering continuous current. Compared with conventional DBS, the adaptive approach appears to provide comparable motor benefit with lower total stimulation and fewer side effects in selected patients. It is an emerging option for people with advanced Parkinson's whose symptoms fluctuate through the day. *
doi.orgJapan approves first iPSC-derived Parkinson's cell therapy
Nature Biotechnology reports that Japan's Ministry of Health granted conditional, time-limited marketing approval to Amchepry (raguneprocel), an allogeneic iPSC-derived dopaminergic neuron replacement therapy developed by Sumitomo Pharma. The approval is a regulatory first for an iPSC-based Parkinson's treatment and currently applies only to eligible patients within the Japanese healthcare system. It marks a milestone for cell-replacement therapy but is not yet available in the United States or Europe. *
nature.com
Lifestyle Interventions
Walking and dance exercise improve motor function
A network meta-analysis of 67 randomized controlled trials covering 2,642 Parkinson's patients found that walking training and dance training significantly improved motor function, while aquatic training provided the largest gains in quality of life. The review supports personalized exercise prescriptions matched to a patient's main symptom burden rather than one-size-fits-all activity. For families, this means a treadmill walk or a dance class may be among the most evidence-backed non-drug options available today. *
frontiersin.orgPhysiotherapy dose-response mapped for balance
A dose-response meta-analysis in npj Parkinson's Disease reviewed physiotherapy interventions for balance impairment, a symptom poorly controlled by medication. The authors identified optimal session frequency, duration, and exercise type that produce measurable gains in postural stability and fall-related outcomes. Patients and families can use these dose targets when discussing a physical therapy referral to maximize real-world mobility benefit. *
nature.comMediterranean diet plus exercise trial launched
The PRIME study protocol describes a multicenter randomized controlled pilot trial enrolling 80 Parkinson's patients into four arms: Mediterranean diet alone, structured physical activity, both combined, or standard care. Primary outcomes include gut microbiome shifts and disease progression markers over the intervention period. While the trial is still enrolling, the protocol signals that combined lifestyle protocols are now being tested as candidate disease-modifying interventions. *
frontiersin.org
Emerging Research
Fecal transplant improves motor symptoms in early trial
A randomized phase 2 trial in drug-naive Parkinson's patients showed that repeated donor fecal microbiota transplantation was safe and produced meaningful improvements in motor scores and bowel symptoms. The study provides mechanistic evidence that targeting the gut microbiome could become a non-pharmacologic therapy for newly diagnosed patients. *
nature.comGut microbiome signature tracks progression
Researchers profiled the gut microbiome across healthy individuals, those genetically at risk for Parkinson's, and diagnosed patients, finding a dysbiosis signature that deepens with disease. The work could lead to a stool-based screening tool that flags elevated risk years before motor symptoms appear. *
nature.comGut ecosystem changes flagged as early biomarker
A study linking the fecal metabolome and metagenome in Parkinson's disease identified altered microbial metabolites tied to gut ecosystem dysfunction. The findings add candidate biomarkers that could eventually help clinicians detect or stage Parkinson's earlier than current methods allow. *
nature.com
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.